₹266.5
-2.02% today
· 30d +20.59%
as of 2026-09-04
Price · Daily Candles
“Indoco Remedies' Q4 Loss Widens Amidst Sharp Revenue Growth and Bearish Signals”
While Indoco Remedies reported strong Q4 revenue growth of +21.89% YoY to ₹476 Cr, the company posted a net loss of ₹-24 Cr, reversing its prior Q4 profit. Operating profit surged by 3905.65% to ₹50 Cr, but this quarter's net loss contributes to the annual net loss of ₹-99 Cr, marking a significant profitability challenge despite 10.84% annual revenue growth.
BULL CASE
+Q4 revenue grew +21.89% YoY to ₹476 Cr, demonstrating robust sales momentum.
+Operating profit showed a significant rebound in Q4, increasing by 3905.65% YoY to ₹50 Cr, with OPM rising by 10.13 percentage points.
+The stock is trading at a significant margin of safety, with its current price of ₹192 well below the intrinsic value of ₹1212.4, suggesting it is undervalued.
+Promoter holding remains high at 58.86% as of Q4 2026, indicating continued insider confidence.
BEAR CASE
−Indoco Remedies recorded a net loss of ₹-24 Cr in Q4 2026 and an annual net loss of ₹-99 Cr, indicating profitability struggles.
−The stock has seen substantial price declines, down -26.23% over the past year and -45.11% from its 52-week high of ₹349.8.
−Technical indicators MACD and RSI(14) are bearish, with values of -4.0896 and 36.12 respectively, alongside a 'weak' technical score of 30.
−FIIs reduced their stake by -0.16% QoQ in Q4 2026, while public shareholding increased by 0.13% QoQ.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹468 Cr
+6.76% YoY
NET PROFIT
₹65 Cr
OPM
9.2%
+4.84pp YoY
EPS
₹7.09
Intrinsic value · DCF: N/A — ML model predicts severe Δ FCF compression (h1=-46.9%, h2=-48.3%, h3=-45.0% of mktcap), driving projected FCF negative by year 3 despite healthy current FCF. Treating as forecast outlier rather than reporting a misleading ₹0 valuation. Use the Strategy Fit and ML sections instead.
◇ Sector Position
Indoco Remedies with a ROCE of 1.0% lags significantly behind peers like Dr. Reddy's (ROCE 27.63%) and Cipla (ROCE 25.09%), indicating substantial underperformance in capital efficiency.
PEERPEROCE %
INDOCO797.11.0
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒
47
SCORE / 100
Overall
6-axis composite of the sections below.
Performance
POSITIVE
55
Valuation
STRETCHED
5
Growth
STEADY
59
Profitability
AVERAGE
42
Technicals
STRONG
73
Risk
MODERATE
50
Key Stats
P/B
1.73
52W HIGH
₹332.2
OFF HIGH
-19.78%
DIV YIELD
0.1%
MKT CAP
₹2471 Cr
◉ Active Signals
MACDBullish5.3393
RSI(14)Bullish67.54
Street Consensus
4 analysts₹276.25
mean target
Low ₹250.0Now ₹266.5High ₹325.0
⧉ Strategy Fit 🔒